More specifically, the favorable effect of NOTCH1 mutations in BFM protocols is highly significant in the standard and intermediate risk groups, whereas NOTCH1 mutations are neutral in the high-risk group that consists of patients with poor early treatment response.
← all excerpts
The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function.
1
—
—